Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma
Completed · Phase 2
Conditions studied: Central Nervous System Tumor, Pediatric, Neuroblastoma
In brief
RATIONALE: Thalidomide may stop the growth of tumor cells by stopping blood flow to the tumor. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining thalidomide with temozolomide may kill more tumor cells. PURPOSE: This phase II trial is studying the effectiveness of combining thalidomide with temozolomide in treating young patients who have relapsed or progressive brain tumors or recurrent neuroblastoma.
Key facts
- Study ID
- NCT00098865
- Run by
- Dana-Farber Cancer Institute
- People needed
- 15
- Starts
- 2002-09-01
- Expected to finish
- 2010-06-01
- Last updated by the study team
- 2014-10-07
Who can join
Age: any, up to 21. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Dana Farber Cancer Institute — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.